Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Cymbalta Diabetic Pain Launch To Piggyback On Depression Roll-Out

Executive Summary

Lilly's launch of two Cymbalta indications will highlight the utility of duloxetine in treating both emotional distress and physical pain

You may also be interested in...



Pfizer Lyrica Launch Awaits Controlled Substance Scheduling

Pfizer's launch of Lyrica will be delayed while pregabalin undergoes controlled substance scheduling at the Drug Enforcement Administration

Pfizer Lyrica Launch Awaits Controlled Substance Scheduling

Pfizer's launch of Lyrica will be delayed while pregabalin undergoes controlled substance scheduling at the Drug Enforcement Administration

Cymbalta “Mood” And “Pain” Claims May Include Fibromyalgia And Anxiety

Lilly is pursuing fibromyalgia and generalized anxiety disorder indications to add to the two currently approved indications for Cymbalta

Related Content

Topics

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel